Effect of Preoperative Immunonutrition in Upper Digestive Tract
Primary Purpose
Immunonutrition, Gastric Cancer, Esophageal Cancer
Status
Unknown status
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Immunonutrition
Standard
Sponsored by
About this trial
This is an interventional supportive care trial for Immunonutrition focused on measuring immunonutrition, surgery, postoperative complications, length of hospital stay, nutritional status
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of cancer of esophagus, stomach and / or pancreas, at any stage, proposed for surgery
- Signing informed consent
Exclusion Criteria:
- Pregnant or breastfeeding
- Advanced renal insufficiency prior to dialysis (GFR <25 ml / min)
- Allergy or intolerance to any of the components of the dietary supplement (including fish allergy)
- Patients with contraindications for enteral nutrition
Sites / Locations
- Miguel A. Martínez OlmosRecruiting
- Alfonso Vidal-CasariegoRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Immunonutrition
Standard
Arm Description
Oral nutritional supplement: hypercaloric and hyperproteic with immunonutrients: Arginine, nucleotides, omega-3, olive oil polyphenols, antioxidants and L-carnitine
Oral nutritional supplement: hypercaloric and hyperproteic without immunonutrients
Outcomes
Primary Outcome Measures
Infectious complications
Surgical fistulas
Secondary Outcome Measures
Mortality
Length of hospital stay
Weight loss
Full Information
NCT ID
NCT04027088
First Posted
July 16, 2019
Last Updated
August 19, 2019
Sponsor
Complexo Hospitalario Universitario de A Coruña
1. Study Identification
Unique Protocol Identification Number
NCT04027088
Brief Title
Effect of Preoperative Immunonutrition in Upper Digestive Tract
Official Title
Multicenter Randomized Clinical Trial of the Effect of Preoperative Immunonutrition Versus Standard Enteral Nutrition in Elective Oncological Surgery of the Upper Digestive Tract
Study Type
Interventional
2. Study Status
Record Verification Date
August 2019
Overall Recruitment Status
Unknown status
Study Start Date
August 10, 2019 (Actual)
Primary Completion Date
August 10, 2021 (Anticipated)
Study Completion Date
December 31, 2021 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Complexo Hospitalario Universitario de A Coruña
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Randomized, double-blind, multicenter clinical trial that will evaluate the effects of immuno-nutrition in the preoperative period in patients with cancer of the upper digestive tract (esophagus, stomach, and pancreas). The aim is to compare the specific effect of the immunonutrients respect to an equivalent formula in caloric-protein value but without immunonutrients, in the surgical evolution of the cancer patient.
Detailed Description
Background:
Perioperative nutritional status is a key factor in the evolution, as well as, postoperative morbidity and mortality of cancer patients. Particularly, digestive neoplasms have a high risk of malnutrition and this is related to a higher rate of surgery complications and mortality in the postoperative period. The immunonutrition seems to modulate the immune system and the inflammatory response in patients operated on for digestive neoplasia. However, the results to date are controversial.
Aim:
To compare the effect of an immunomodulatory oral nutritional supplement (enriched in arginine, nucleotides, omega 3 fatty acids, olive oil polyphenols, L-carnitine, and antioxidants) against an equivalent in protein-energy without immunonutrients, administrated in the preoperative period, in the surgical evolution of the cancer patient with neoplasia of the upper digestive tract.
Methods:
It is a randomized, double-blind, multicenter clinical trial. 178 patients with neoplasms of the esophagus, stomach or pancreas, with indication of surgical treatment, will be included. The patients will be randomized into two groups (intervention group and control group) and both will receive 2 daily bricks of the assigned formula (with or without immunonutrients, respectively) 5 days prior to surgery. The main variables of the study are: appearance of infectious or noninfectious complications in the postoperative period, length of hospital stay, and mortality. These variables will be compared by group (immunonutrition vs. non immunonutrition).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Immunonutrition, Gastric Cancer, Esophageal Cancer, Pancreas Cancer, Surgery--Complications
Keywords
immunonutrition, surgery, postoperative complications, length of hospital stay, nutritional status
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
178 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Immunonutrition
Arm Type
Experimental
Arm Description
Oral nutritional supplement: hypercaloric and hyperproteic with immunonutrients: Arginine, nucleotides, omega-3, olive oil polyphenols, antioxidants and L-carnitine
Arm Title
Standard
Arm Type
Placebo Comparator
Arm Description
Oral nutritional supplement: hypercaloric and hyperproteic without immunonutrients
Intervention Type
Dietary Supplement
Intervention Name(s)
Immunonutrition
Other Intervention Name(s)
Bi1 procare
Intervention Description
It is a hypercaloric and hyperproteic dietary supplement formulated with immunonutrients: Arginin, nucleotides, omega-3, olive oil polyphenols, antioxidants and L-carnitine
Intervention Type
Dietary Supplement
Intervention Name(s)
Standard
Intervention Description
It is a hypercaloric and hyperproteic dietary supplement formulated without immunonutrients
Primary Outcome Measure Information:
Title
Infectious complications
Time Frame
Up to 30 days post-operative
Title
Surgical fistulas
Time Frame
Up to 30 days post-operative
Secondary Outcome Measure Information:
Title
Mortality
Time Frame
Up to 30 days post-operative
Title
Length of hospital stay
Time Frame
Up to 30 days post-operative
Title
Weight loss
Time Frame
10 days Pre-operative
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosis of cancer of esophagus, stomach and / or pancreas, at any stage, proposed for surgery
Signing informed consent
Exclusion Criteria:
Pregnant or breastfeeding
Advanced renal insufficiency prior to dialysis (GFR <25 ml / min)
Allergy or intolerance to any of the components of the dietary supplement (including fish allergy)
Patients with contraindications for enteral nutrition
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Alfonso Vidal-Casariego, PhD, MD
Phone
+34981176442
Email
alfonso.vidal.casariego@sergas.es
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Miguel Á Martínez-Olmos, PhD, MD
Organizational Affiliation
Complexo Hospitalario Universitario de Santiago
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Alfonso Vidal-Casariego, PhD, MD
Organizational Affiliation
Complexo Hospitalario Universitario de A Coruña
Official's Role
Principal Investigator
Facility Information:
Facility Name
Miguel A. Martínez Olmos
City
Santiago De Compostela
State/Province
A Coruña
ZIP/Postal Code
15701
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Miguel A Martínez Olmos, MD PhD
First Name & Middle Initial & Last Name & Degree
Miguel A Martínez Olmos, MD PhD
First Name & Middle Initial & Last Name & Degree
Ana Cantón Blanco, MD PhD
First Name & Middle Initial & Last Name & Degree
Rocío Villar Taibo, MD PhD
First Name & Middle Initial & Last Name & Degree
Alicia Santamaría Nieto, MD
First Name & Middle Initial & Last Name & Degree
Ana B Crujeiras, BSc PhD
First Name & Middle Initial & Last Name & Degree
Ana Suárez Rodríguez, BSc
Facility Name
Alfonso Vidal-Casariego
City
A Coruña
State/Province
La Coruna
ZIP/Postal Code
15006
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alfonso Vidal-Casariego, MD, PhD
Phone
+34981176442
Email
alfonso.vidal.casariego@sergas.es
First Name & Middle Initial & Last Name & Degree
Alfonso Vidal-Casariego, MD, PhD
First Name & Middle Initial & Last Name & Degree
Francisco Pita-Gutiérrez, MD, PhD
First Name & Middle Initial & Last Name & Degree
Gloria Lugo-Rodríguez, MD
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Effect of Preoperative Immunonutrition in Upper Digestive Tract
We'll reach out to this number within 24 hrs